- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02207946
Botulinum Toxin A to Treat Arm Tremor
February 11, 2021 updated by: Merz Pharmaceuticals GmbH
Prospective, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of the Efficacy and Safety of NT 201 in the Unilateral Treatment of Essential Tremor of the Upper Limb
The objective of this study is to assess the efficacy and safety of a single, kinematic-analysis-based intramuscular injection of NT 201, compared with placebo, in moderate to marked essential tremor of the upper limb.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
30
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Manitoba
-
Winnipeg, Manitoba, Canada, R3J2H7
- Merz Investigational Site #0010317
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canada, B3P 1M3
- Merz Investigational Site #0010089
-
-
Ontario
-
Toronto, Ontario, Canada, M5T 2S8
- Merz Investigational Site #0010078
-
Toronto, Ontario, Canada, M6M 2J5
- Merz Investigational Site #0010305/1
-
Toronto, Ontario, Canada, M6M 2J5
- Merz Investigational Site #0010305/2
-
-
-
-
New York
-
New York, New York, United States, 10029
- Merz Investigational Site #0010191
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Main Inclusion Criteria:
Diagnosis of 'definite essential tremor' in accordance with modified TRIG criteria, as follows:
- Bilateral postural tremor with or without kinetic tremor, involving hands and forearms, that is visible and persistent.
- It is to be noted that:
- Tremor of other body parts may be present in addition to upper limb tremor.
- Bilateral tremor may be asymmetric.
- Tremor is reported by patient to be persistent, although the amplitude may fluctuate.
- First onset of essential tremor at least 6 months before screening with stability of the tremor symptoms over 4 weeks and in the opinion of the investigator definite diagnosis of essential tremor.
- Moderate-to-marked upper-limb postural and/or kinetic tremor at wrist level, corresponding to Fahn-Tolosa-Marin upper-limb tremor rating of at least 2 categories (scale part C, items 16-23) in the limb to be treated between of 2 or higher.
- Visible tremor at wrist level in at least one of the four positions/tasks used in kinematic assessments
- Tremor deemed by the investigator to require a treatment with 30 - 200 U NT 201 for a treatment of up to three joints of the selected upper limb (wrist treatment mandatory).
- Stable concomitant anti-tremor medication and no clinically relevant findings in routine laboratory examinations.
Main Exclusion Criteria:
- Any neurological signs abnormal for the subject's age, other than the tremor itself and Froment's maneuver.
- Exposure to the following tremorogenic drugs: Lithium, Valproic acid, Amiodarone, typical and atypical neuroleptics. Exposure to other than the listed tremorogenic or potentially tremorogenic drugs is allowed only if, in the opinion of the investigator, this will not interfere with the study drug evaluation. In these cases, a stable medication should be reached 4 weeks before screening and intended for the time during the study drug evaluation.
- Trauma to the central nervous system or the nerves of the target limb within the three months preceding the onset of tremor.
- Evidence of psychogenic origins of tremor.
- Life habits (e.g. smoking, alcohol or substance abuse) prejudicial to study participation.
- Prior surgery to treat tremor
- Recent (16 weeks) treatment with any Botulinum toxin product for any reason.
- Relevant recent or planned surgery or other specified relevant treatments and/or concomitant disorders.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 200 Units incobotulinumtoxinA (Xeomin)
Single injection cycle, total dose of up to 200 Units, intramuscular injection into muscles of wrist (mandatory) and shoulder and/or elbow (both optional).
|
Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins.
Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
Other Names:
|
Placebo Comparator: Placebo
Single injection cycle, intramuscular injection into muscles of wrist (mandatory) and shoulder and/or elbow (both optional).
|
Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline to Week 4 in Maximum Angular Tremor Amplitude of the Wrist (Injected Limb)
Time Frame: Baseline up to Week 4
|
No primary efficacy variables are defined for this study.
One of the secondary outcome measures is used for CTgov protocol registration and results reporting purposes only.
TremorTek is a tremor kinematic analytics investigational device which is used to measure maximum angular tremor amplitude at wrist of the injected limb (unit: degrees).
Angular tremor amplitude is the measure of tremor severity.
Reduction of angular tremor amplitude at wrist of the injected limb represents tremor improvement.
|
Baseline up to Week 4
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline to Week 4 in Maximum Log-transformed Accelerometric Tremor Amplitude at Wrist Level (Injected Limb)
Time Frame: Baseline up to Week 4
|
TremorTek is a tremor kinematic analytics investigational device which is used to measure maximum log-transformed accelerometric tremor amplitude at wrist level of the injected limb (unit: meter per square second [m/s˄2]).
Log-transformed accelerometric tremor amplitude is a measure of tremor severity reflecting the non-vectoral intensity of tremor.
Reduction of log-transformed accelerometric tremor amplitude at wrist level of the injected limb represents a tremor improvement.
|
Baseline up to Week 4
|
Change From Baseline to Week 4 in Fahn-Tolosa-Marin (FTM) Tremor Score in Injected Limb (Item 5 [Right Upper Extremity] or 6 [Left Upper Extremity])
Time Frame: Baseline up to Week 4
|
The FTM tremor rating scale is used for evaluation of tremor severity and function and consists of three parts (A, B, C).
For this outcome measure the score of FTM scale item 5 ("right upper extremity") or item 6 ("left upper extremity") is used (both items are from part A).
The outcome values are calculated as the sum of the three functions "at rest", "with posture holding", and "with action and intention".
The score for each item ranges from 0 (normal) to 4 (severe), that is, the possible values range from 0 to 12.
|
Baseline up to Week 4
|
Change From Baseline to Week 4 in FTM Motor Performance Score (Items 11-15)
Time Frame: Baseline up to Week 4
|
The FTM tremor rating scale was used for evaluation of tremor severity and function.
This investigator-assessed scale consists of 3 parts (A, B and C).
Part A: Tremor location/Severity rating (items 1-10); Part B: Specific motor tasks / Function rating (items 11-15).
Ratings for five motor tasks (handwriting, drawing [large/small spiral, line], and pouring); and Part C: Functional disabilities resulting from tremor/activities of daily living (items 16-23).
For this outcome measure, the sum of the five FTM motor performance items (from Part B) were used: item 11 ('handwriting for dominant hand only' - irrespective of its injection or non-injection), items 12 to 15 ('drawing large and small spiral', 'line drawing', 'pouring' for the injected upper limb).
The score for each item ranges from 0 (normal) to 4 (severe).
Possible values range for total FTM motor performance score: 0-20.
|
Baseline up to Week 4
|
Participant's Global Impression of Change Scale (GICS) at Week 4
Time Frame: Week 4
|
The GICS was used to measure the participant's impression of change due to treatment.
The response option was a common 7-point Likert scale, with the following values: +3 (very much improved); +2 (much improved); +1 (minimally improved); 0 (no change); -1 (minimally worse); -2 (much worse); -3 (very much worse).
|
Week 4
|
Investigator's Global Impression of Change Scale (GICS) at Week 4
Time Frame: Week 4
|
The GICS was used to measure the investigator's impression of change due to treatment.
The response option was a common 7-point Likert scale, with the following values: +3 (very much improved); +2 (much improved); +1 (minimally improved); 0 (no change); -1 (minimally worse); -2 (much worse); -3 (very much worse).
|
Week 4
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 5, 2014
Primary Completion (Actual)
May 9, 2016
Study Completion (Actual)
September 26, 2016
Study Registration Dates
First Submitted
August 1, 2014
First Submitted That Met QC Criteria
August 1, 2014
First Posted (Estimate)
August 4, 2014
Study Record Updates
Last Update Posted (Actual)
February 18, 2021
Last Update Submitted That Met QC Criteria
February 11, 2021
Last Verified
February 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Central Nervous System Diseases
- Nervous System Diseases
- Neurologic Manifestations
- Movement Disorders
- Dyskinesias
- Tremor
- Essential Tremor
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Cholinergic Agents
- Membrane Transport Modulators
- Acetylcholine Release Inhibitors
- Neuromuscular Agents
- Botulinum Toxins
- Botulinum Toxins, Type A
- abobotulinumtoxinA
- incobotulinumtoxinA
Other Study ID Numbers
- MRZ60201_2094_1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Essential Tremor of the Upper Limbs
-
Merz Pharmaceuticals GmbHCompletedEssential Tremor of the Upper LimbUnited States, Canada, Poland
-
University of MinnesotaRecruitingEssential Tremor | Upper Extremity Essential TremorUnited States
-
Assistance Publique Hopitaux De MarseilleUnknown
-
AbbVieRecruitingUpper Limb Essential Tremor (UL ET)United States, Canada
-
Syracuse UniversityNational Institute on Deafness and Other Communication Disorders (NIDCD)CompletedEssential Voice Tremor | Voice Tremor | Vocal Tremor | Essential Tremor of VoiceUnited States
-
Hospices Civils de LyonRecruitingBilateral Traumatic Amputation of Upper LimbsFrance
-
University Hospital, AngersUnknownObliterating Arteriopathy of the Lower LimbsFrance
-
Instituto de Investigación Hospital Universitario...Hospital Universitario La PazCompletedNonrevascularizable Critical Ischemia of the Lower LimbsSpain
-
Isfahan University of Medical SciencesCompletedClosed Multiple Fractures of Upper and Lower Limbs
-
University of ZurichJaenckeUnknownInjury of the Right Upper ExtremitySwitzerland
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States